The results demonstrated that the mRNA levels of RUNX2 were significantly higher in recurrent tumors and metastatic sites than those of non-recurrent ones (Fig. 8a), and the mRNA levels were closely associated with CRC TMN stages and liver/lung metastasis (Table 1). Here, RUNX2 is linked to therapy-related myeloid neoplasm.